Additional file 1: Figures S1 and S2

Time series analysis of neoadjuvant chemotherapy and bevacizumab treated breast carcinomas reveals a systemic shift in genomic aberrations

Elen Kristine Höglander[1,2], Silje Nord[1,2], David C Wedge[3], Ole Christian Lingjærde[2,4], Laxmi Silwal-Pandit[1,2], Hedda vdL Gythfeldt[1,5], Hans Kristian Moen Vollan[1,2,5], Thomas Fleischer[1, 2], Marit Krohn[1,2], Ellen Schlitchting[6], Elin Borgen[7], Øystein Garred[7], Marit M Holmen[8], Erik Wist[5], Bjørn Naume[2,5], Peter Van Loo[9], Anne-Lise Børresen-Dale[1,2], Olav Engebraaten[2,5,], Vessela Kristensen[1,2,10,*]*

[1] Department of Genetics, Oslo University Hospital, Oslo, Norway.

[2] KG Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Norway.

[3] Big Data Institute, University of Oxford, Oxford, UK.

[4] University of Oslo, Biomedical Informatics, Department of Informatics and Centre for Cancer Biomedicine, Oslo, Norway.

[5] Department of Oncology, Oslo University Hospital, Oslo, Norway.

[6] Section for Breast and Endocrine Surgery, Oslo University Hospital, Oslo, Norway.

[7] Department of Pathology, Oslo University Hospital, Oslo, Norway.

[8] Department of Radiology, Oslo University Hospital, Oslo, Norway.

[9] Cancer Research UK London Research Institute, London, UK.

[10] Department of Clinical Molecular Biology (EpiGen), Divison of Medicine, Akershus University Hospital, Lørenskog, and University of Oslo, Norway.



Figure S1: A. GII in untreated tumors within the two therapy arms. **B.** Frequency plots of genome wide aberration score for tumors at the time of diagnosis in the Combination-arm (top) and the Chemotherapy-arm (bottom).



Figure S2: Number of patients showing an increase (green) or a decrease (red) in the clonality of copy number changes genome wide between diagnosis and 12 weeks after treatment: copy number losses in responders (**A**) and non-responders (**B**); LOH in responders (**C**) and non-responders (**D**); gains in responders (**E**) and non-responders (**F**).